IN2015DN01018A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01018A
IN2015DN01018A IN1018DEN2015A IN2015DN01018A IN 2015DN01018 A IN2015DN01018 A IN 2015DN01018A IN 1018DEN2015 A IN1018DEN2015 A IN 1018DEN2015A IN 2015DN01018 A IN2015DN01018 A IN 2015DN01018A
Authority
IN
India
Prior art keywords
acetoxy
propoxy
diphenyl
alkyl
methyl
Prior art date
Application number
Inventor
Smith Kathleen E Clarence
Thomas N Chase
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of IN2015DN01018A publication Critical patent/IN2015DN01018A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms

Abstract

There are described new l-alkyl-l-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halides and pharmaceutical compositions comprising a l-alkyl-l-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halide as an active ingredient. These products are non-selective muscarinic acetylcholine receptor antagonists acting in the periphery and not in the brain.
IN1018DEN2015 2012-08-09 2013-07-30 IN2015DN01018A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681415P 2012-08-09 2012-08-09
PCT/US2013/052626 WO2014025569A1 (en) 2012-08-09 2013-07-30 Piperidinium quaternary salts

Publications (1)

Publication Number Publication Date
IN2015DN01018A true IN2015DN01018A (en) 2015-06-26

Family

ID=50068488

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1018DEN2015 IN2015DN01018A (en) 2012-08-09 2013-07-30

Country Status (14)

Country Link
US (1) US9896416B2 (en)
EP (1) EP2882711B1 (en)
JP (1) JP6345665B2 (en)
KR (2) KR102240999B1 (en)
CN (2) CN108658842A (en)
AU (1) AU2013300009B2 (en)
BR (1) BR112015002832B1 (en)
CA (1) CA2881182C (en)
EA (1) EA029678B9 (en)
HK (1) HK1211572A1 (en)
IL (1) IL236996A0 (en)
IN (1) IN2015DN01018A (en)
MX (1) MX356386B (en)
WO (1) WO2014025569A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596139B2 (en) 2015-03-06 2020-03-24 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2017015349A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
CA3151141C (en) 2019-08-22 2024-01-16 Ofinno, Llc Policy control for multiple accesses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD106643A1 (en) * 1973-07-12 1974-06-20
CN1285348A (en) 1999-08-20 2001-02-28 广东康美药业股份有限公司 Process for synthesizing propiverine hydrochloride
DE10129832A1 (en) * 2001-06-17 2003-07-10 Berolina Drug Dev Ab Svedala Deuterated N- and alpha-substituted diphenylalkoxyacetic acid amino alkyl esters and medicaments containing these compounds
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
KR100510788B1 (en) 2003-07-22 2005-08-26 동방에프티엘 주식회사 Process for preparation of the propiverine hydrochloride from O-n-propylbenzylic acid
KR100500760B1 (en) 2003-07-22 2005-07-14 동방에프티엘 주식회사 Process for preparation of the propiverine hydrochloride
CN100569235C (en) * 2004-02-06 2009-12-16 Meda制药有限及两合公司 Be used for the anticholinergic of asthma and COPD long-term treatment and the combination of glucocorticoid
WO2007022208A2 (en) * 2005-08-12 2007-02-22 The Government Of The United States Of America, As Represented By The Secretary, Neuronal avalanche assay
CN1951938A (en) * 2005-10-21 2007-04-25 刘丽娅 Penehyclidine quaternary ammonium salt and its derivative
SE0600876L (en) 2006-04-20 2007-10-21 Sandvik Intellectual Property Tools and inserts for chip separating machining with primary and secondary meshes with rotationally symmetrical shape
CN101490003A (en) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder
JP2009534463A (en) * 2006-04-24 2009-09-24 アストラゼネカ・アクチエボラーグ Novel alkyl esters of cyclic amino alcohols with muscarinic M3 receptor antagonist activity useful for the treatment of, for example, chronic bronchial obstruction, asthma and overactive bladder
EP2470504B1 (en) * 2010-03-15 2013-10-16 Ramesha Andagar Ramakrishna Synthesis of propiverine hydrochloride
KR101149821B1 (en) 2010-04-05 2012-05-24 하나제약 주식회사 Novel synthetic method of diphenylacetate derivatives
CN102218063B (en) 2011-04-12 2013-03-13 贵州神奇制药有限公司 Method for preparing propiverine hydrochloride medicaments, and product and detection method thereof
CA2882407C (en) * 2012-09-05 2022-11-15 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods

Also Published As

Publication number Publication date
WO2014025569A1 (en) 2014-02-13
BR112015002832A2 (en) 2017-07-04
AU2013300009A1 (en) 2015-02-26
EP2882711B1 (en) 2017-10-25
IL236996A0 (en) 2015-03-31
CN108658842A (en) 2018-10-16
EA029678B9 (en) 2018-07-31
US20150203452A1 (en) 2015-07-23
MX356386B (en) 2018-05-28
US9896416B2 (en) 2018-02-20
KR102240999B1 (en) 2021-04-15
MX2015001769A (en) 2015-05-08
CN104603108A (en) 2015-05-06
EP2882711A1 (en) 2015-06-17
KR20200022522A (en) 2020-03-03
BR112015002832B1 (en) 2022-08-16
JP2015524469A (en) 2015-08-24
CA2881182A1 (en) 2014-02-13
JP6345665B2 (en) 2018-06-20
EA201500209A1 (en) 2015-05-29
EA029678B1 (en) 2018-04-30
EP2882711A4 (en) 2016-02-10
CA2881182C (en) 2021-01-26
KR20150040355A (en) 2015-04-14
AU2013300009B2 (en) 2017-06-15
HK1211572A1 (en) 2016-05-27

Similar Documents

Publication Publication Date Title
EA201290984A1 (en) PHARMACEUTICAL PHARMACEUTICAL COMPOSITIONS, PREVENTING ABUSE
MX2015016171A (en) Azetidine estrogen receptor modulators and uses thereof.
AU2013235499A8 (en) Estrogen receptor modulators and uses thereof
ZA201405101B (en) "new indolizine compounds, a process for their preparation and pharmaceutical compositions containing them."
EA201201263A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
EP2982367A4 (en) Pharmaceutical composition for parenteral administration, containing donepezil
MX2018003096A (en) Pharmaceutical composition containing anionic drug, and preparation method therefor.
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
IN2015DN03984A (en)
IL236057B (en) 1,2,4-triazine-6-carboxamide derivatives and pharmaceutical compositions comprising them
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
MX2016008369A (en) Pharmaceutical composition containing palonosetron.
UY34730A (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE CCR3 ANTAGONISTS
EA201201202A1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANE EXTILE
PH12015501115B1 (en) Learning and memory improver
MX2016001138A (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof.
PH12014502856A1 (en) Solid pharmaceutical preparation containing levothyroxine
IL246298B (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
MD20150053A2 (en) Co-micronisation product comprising ulipristal acetate
MY183068A (en) Pharmaceutical formulation comprising antibody
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
IN2015DN01018A (en)
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines